Interleukin-7(Cytheris SA)(Interleukin-7(Cytheris SA)) - 药物靶点：IL-7Rα_在研适应症：肿瘤，多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

白细胞介素

别名

Glycosylated recombinant human interleukin-7、IL-7、Interleukin 7

+ [10]

靶点

IL-7Rα

作用机制

IL-7Rα激动剂(白细胞介素-7受体α亚基激动剂)、免疫调节剂

治疗领域

肿瘤免疫系统疾病心血管疾病+ [1]

在研适应症

肿瘤多发性骨髓瘤

非在研适应症

急性髓性白血病伯基特淋巴瘤慢性期慢性髓性白血病+ [13]

原研机构

Cytheris SA

在研机构

RevImmune, Inc.

非在研机构

Cytheris SACytheris, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 168681

关联

33

项与 Interleukin-7(Cytheris SA) 相关的临床试验

NCT06523699 / Not yet recruiting临床1期IIT

A Pilot Study of the Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

This is a two-arm, open-label, randomized, single-site, pilot study testing the addition of CYT107 following autologous hematopoietic cell transplant (AHCT) in patients with multiple myeloma (MM). The hypothesis of this study is that recombinant human CYT107 can be safely administered after AHCT and will promote quantitative and qualitative T cell reconstitution, which will be associated with enhanced tumor cell clearance and reduced infectious complications. Patients will be randomized to either the intervention arm that will receive CYT107 + standard of care melphalan and AHCT or to the control arm that will receive standard of care melphalan and AHCT only.

开始日期2025-01-31

申办/合作机构

Washington University School of Medicine

[+1]

NCT04927169 / Terminated临床2期

Recombinant Human InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic PAtients With COVID-19 Infection - "ILIAD 7 Trial" Brazil Cohort

Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

开始日期2021-03-01

申办/合作机构

RevImmune, Inc.

NCT04426201 / Terminated临床2期

A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort

Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

开始日期2020-12-20

申办/合作机构

RevImmune, Inc.

[+4]

100 项与 Interleukin-7(Cytheris SA) 相关的临床结果

登录后查看更多信息

100 项与 Interleukin-7(Cytheris SA) 相关的转化医学

登录后查看更多信息

100 项与 Interleukin-7(Cytheris SA) 相关的专利（医药）

登录后查看更多信息

649

项与 Interleukin-7(Cytheris SA) 相关的文献（医药）

2024-12-01·Food Chemistry-X

Immunomodulatory peptides from sturgeon cartilage: Isolation, identification, molecular docking and effects on RAW264.7 cells

Article

作者: An, Miaoqing ; Du, Bing ; Zhao, Yuxuan ; Zhao, Wenjun ; Li, Shuchan ; Li, Pan

Sturgeons (Acipenseridae), ancient fish known for their caviar, produce underutilized by-products like protein-rich cartilage, which is a source of high-quality bioactive peptides. This study investigates immunomodulatory peptides from sturgeon cartilage hydrolysates mechanisms. The study found that sturgeon cartilage hydrolysate F2-7 and its key peptides(DHVPLPLP and HVPLPLP)significantly promoted RAW267.4 cell proliferation, NO release, and phagocytosis (P < 0.001).Additionally, western blotting confirmed that F2-7 enhances immune response by increasing the expression of P-IKKα/β, IΚΚ, p65, and P-p65 proteins in the NF-κB signalling pathway (P < 0.01). Molecular docking further demonstrated that DHVPLPLP and HVPLPLP bind to NF-κB pathway proteins via hydrogen bonding, with low estimated binding energies (-2.75 and -1.64; -6.04 and -4.75 kcal/mol), thus establishing their role as key immune peptides in F2-7. Therefore, DHVPLPLP and HVPLPLP have the potential to be developed as dietary supplements for immune enhancement. Their ability to enhance immune function provides a theoretical basis for novel immune supplements.

2024-12-01·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Therapeutic impact of a benzofuran derivative on Aluminium chloride-induced Alzheimer's disease-like neurotoxicity in rats via modulating apoptotic and Insulin 1 genes

Article

作者: El-Rigal, Nagy S. ; Aly, Hanan F ; Aly, Hanan F. ; Ibrahim Fouad, Ghadha ; Khalil, Wagdy K B ; Mohammed, Faten F. ; Rizk, Maha Z. ; El-Rigal, Nagy S ; Khalil, Wagdy K.B. ; Rizk, Maha Z ; Abd El-Karim, Somaia S. ; Ahmed, Kawkab A ; Ahmed, Kawkab A. ; Abd El-Karim, Somaia S ; Mohammed, Faten F

Neurodegenerative disorders such as Alzheimer's disease (AD) are age-related and are fatal in advanced cases. There is a limited efficacy of drugs used for the management of these diseases. Herein, the neurotherapeutic efficacy of a benzofuran-derivative-7 (BF-7) was investigated. Aluminum chloride (AlCl₃) was employed to induce AD-like brain toxicity in rats. The rats were divided into four groups: Negative control, AlCl₃-induced AD rats (100 mg/kg body weight, orally), AlCl₃-AD induced rats treated with BF-7 (10 mg/kg body weight, orally), AlCl₃-AD-induced rats treated with the standard drug "Donepezil" (10 mg/kg body weight, orally). The behavioral performance was tested using a beam-balance test. Brain and serum acetylcholinesterase (AChE) activities and the brain levels of norepinephrine, dopamine (DA), and serotonin (5-HT) were measured. The genetic expression of Bcl-2, Bax, caspase-3, and insulin 1 were assayed. The histopathological imaging and the immunohistochemical evaluation of Glial Fibrillary Acidic Protein (GFAP) were investigated in the cerebral cortex. Treatment of AD-rats with BF-7 mitigated AlCl₃-induced neurotoxicity by improving motor functions, counteracting apoptosis, and exerting cholinergic functions. In addition, the genetic expression of Insulin 1 was upregulated significantly in AD-induced rats treated with BF-7. This compound could be used as a promising candidate for neurotherapeutic drug discovery against AD or any other toxic brain disorders.

2024-10-01·JOURNAL OF MEDICAL VIROLOGY

The antimicrobial protein RNase 7 directly restricts herpes simplex virus infection of human keratinocytes

Article

作者: Zeitvogel, Jana ; Sodeik, Beate ; Werfel, Thomas ; Gläser, Regine ; Harder, Jürgen ; Döhner, Katinka ; Klug, Ilona ; Rademacher, Franziska

Abstract:

Approximately 22% of moderately to severely affected atopic dermatitis (AD) patients have a history of eczema herpeticum, a disseminated rash primarily caused by herpes simplex virus type 1 (HSV‐1). Reduced activity of antimicrobial peptides may contribute to the increased susceptibility of AD patients to HSV‐1. We previously demonstrated that the antimicrobial protein RNase 7 limits HSV‐1 infection of human keratinocytes by promoting self‐DNA sensing. Here, we addressed whether RNase 7 has any effect on HSV‐1 infection when infecting keratinocytes without exogenously added costimulatory DNA, and which step(s) of the infection cycle RNase 7 interferes with. We quantified viral gene expression by RT‐qPCR and flow cytometry, viral genome replication by qPCR, virucidal effects by plaque titration, and plaque formation and the subcellular localization of incoming HSV‐1 particles by microscopy. Recombinant RNase 7 restricted HSV‐1 gene expression, genome replication, and plaque formation in human keratinocytes. It decreased HSV‐1 immediate‐early transcripts independently of the induction of interferon‐stimulated genes. Its main effect was on intracellular infection processes and not on extracellular virions or virus binding to cells. RNase 7 reduced the amount of cell‐associated capsids and the HSV‐1 envelope glycoprotein D at 3 but not at 0.5 h postinfection. Our data show that RNase 7 directly restricts HSV‐1 infection of human keratinocytes, possibly by promoting the degradation of incoming HSV‐1 particles. This suggests that RNase 7 may limit HSV‐1 spread in the skin and that mechanisms that reduce its activity in the lesional skin of AD patients may increase their susceptibility to eczema herpeticum.

55

项与 Interleukin-7(Cytheris SA) 相关的新闻（医药）

2024-11-03

·生物制药小编

自免的“始作俑者”

促炎细胞因子（TNF-α、IL-17A等）是自免经典的细胞因子，除此之外，对免疫细胞存活、发育、功能有重要影响的细胞因子，可能是始作俑者，IL-7就是其中之一。 IL-7 IL-7也被称为淋巴生成素，属于IL-2/IL-15细胞因子家族。IL-7由骨髓和胸腺基质细胞、肝脏和肠道上皮细胞、内皮细胞、平滑肌细胞、角质形成细胞和活化的树突状细胞分泌。 IL-7与IL-7R结合，IL-7R由一个高亲和力的α亚基（CD127）和一个共同的γ链组成。IL-7R在CD4+和CD8+ T细胞和髓系细胞上有生理表达，但在人B细胞上不表达。 IL-7参与T细胞增殖以及阳性和阴性选择，在抗肿瘤免疫治疗中，起积极作用，被尝试用于肿瘤治疗的各个方向。自免和肿瘤的治疗，是一体两面（一个免疫检查点两个经典药，自免和癌症是“一体两面”），IL-7在自免疾病进展中，起着推动作用。 IL-7与自免脊椎关节炎（SpA）脊椎关节炎（SpA）中检测到过高水平的IL-7。脊椎关节炎是一组慢性炎症性风湿性疾病，具有特定的病理生理、临床、放射学和遗传特征，炎性腰背痛伴或不伴外周关节炎，加之一定特征的关节外表现是这类疾病特有的症状和体征。本类疾病临床表现的轻重程度差异较大，有的患者病情反复持续进展，有的长期处于相对静止状态，可以正常工作和生活。几种脊柱关节炎病情逐渐进展，都可能发展成典型的强直性脊柱炎，而经过治疗，病情也可能得到控制。除了触发Th17细胞分化，IL-7可以促进先天免疫细胞，如γδT和MAIT细胞极化，导致过量IL-17的分泌。在SpA患者中，先天样T细胞（T γδ、MAIT和ILC3）被认为是IL-17的主要来源，而不是Th17细胞。系统性红斑狼疮（SLE）可溶性(s)IL-7R在系统性红斑狼疮（SLE）患者的血清和尿液中以及肾脏组织中被发现的水平较高。sIL-7R水平也与SLE疾病活性和抗dsDNA抗体浓度相关，并可能预测SLE爆发。有研究假设，IL-7/IL-7R通路有助于破坏SLE免疫耐受的稳定，并创造了遮盖拮抗自身免疫的内源性检查点。因此，IL-7/IL-7R的阻断可能会抑制免疫级联反应失控。 IL-7通过对T细胞的“操纵”，在CD8+效应T细胞的产生和持久性中发挥了特殊的作用，因为这些细胞在SLE患者中检测到的数量更高。此外，IL-7也有助于SLE 中的Th17细胞极化。银屑病（Ps）和银屑病关节炎（PsA）与非病变或正常皮肤相比，银屑病（Ps）活检中IL-7水平显著富集，角质形成细胞是关键来源。与正常个体相比，Ps中的血清IL-7浓度持续增强。但血清IL-7水平不受治疗的影响，其浓度与银屑病面积和严重程度指数（PASI）评分无关；相反，血清IL-6水平与PASI评分之间存在正相关关系。此外，由PsA PBMCs或滑膜液中的IL-7负责破骨细胞的成熟。IL-7通过IL-6非依赖途径与Ps和PsA活动性疾病和骨侵蚀相关。参考资料 Marta B Fernandes, João T Barata ，IL-7 and IL-7R in health and disease: An update through COVID times，Adv Biol Regul. 2023 Jan:87:100940. doi: 10.1016/j.jbior.2022.100940 Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Quarta L et al. , Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis, J. Pathol 212 (2007) 47–55

免疫疗法

2024-09-26

·药精通Bio

新突破！斯坦福大学团队开发出新型人类自身免疫类器官模型

OTC2024类器官前沿应用与3D细胞培养论坛圆满落幕，点击图片可查看会后报告，咨询OTC2025类器官论坛请联系：王晨 180 1628 8769 文章来源：类器官和器官芯片序言 2024年8月，Calvin J. Kuo团队在《Nature》杂志上发表了一篇题为“A human autoimmune organoid model reveals IL-7 function in coeliac disease”的研究文章。这项研究由斯坦福大学医学院的团队领导，他们开发了一种新型的人类自身免疫类器官模型，用于研究乳糜泻（CeD）的病理机制。通过使用空气-液体界面（ALI）技术，研究者们能够从内窥镜活检样本中培养出保留了上皮和原生间质以及组织驻留免疫细胞的十二指肠类器官。这些类器官不仅模拟了CeD患者的病理特征，还揭示了IL-7在调节CD8+ T细胞介导的上皮细胞破坏中的关键作用。研究结果为理解CeD的免疫病理学提供了新的视角，并为开发新的治疗策略提供了潜在的靶点。摘要自身免疫的体外模型受到无法培养受影响的上皮组织以及复杂的组织驻留免疫微环境的限制。乳糜泻（CeD）是一种自身免疫性疾病，其中饮食中的谷蛋白衍生肽与主要组织相容性复合体（MHC）类II人类白细胞抗原分子（HLA）-DQ2或HLA-DQ8结合，引发免疫介导的十二指肠粘膜损伤。在这里，我们从内窥镜活检的完整片段中生成了空气-液体界面（ALI）十二指肠类器官，这些类器官保留了上皮组织以及原生间充质和组织驻留免疫细胞作为一个单元，而不需要重建。ALI类器官的免疫多样性涵盖了T细胞、B细胞和浆细胞、自然杀伤（NK）细胞和髓系细胞，具有广泛的T细胞和B细胞受体库。HLA-DQ2.5限制性的谷蛋白肽选择性地在来自CeD患者的HLA-DQ2.5表达类器官中引发上皮破坏，这可以通过阻断MHC-II或NKG2C/D来抵消。谷蛋白表位刺激了CeD类器官在淋巴细胞和髓系亚群中的免疫网络响应，以及抗转谷氨酰胺酶2（TG2）自身抗体的产生。在CeD类器官的功能研究中发现，白细胞介素-7（IL-7）是一种谷蛋白诱导的致病调节因子，它调节CD8+ T细胞NKG2C/D的表达，并且对上皮破坏是必要且充分的。此外，与采用无谷蛋白饮食的缓解期疾病相比，活跃期CeD患者的活检样本中的内源性IL-7显著上调，主要在固有层间充质中。通过保留上皮组织以及多样化的免疫群体，这种人类体外CeD模型重现了依赖谷蛋白的病理学，使得机制研究成为可能，并为自身免疫病的类器官建模建立了一个原理验证。研究成果图1 人ALI小肠类器官保存上皮细胞、间充质细胞和多种免疫细胞群，而无需外源性重建图2 谷蛋白诱导CeD类器官中的上皮IL-15产生和凋亡图3 醇溶蛋白诱导CeD类器官中T细胞扩增图4 谷蛋白诱导CeD类器官的网络适应性和先天性免疫反应图5 IL-7在谷蛋白诱导的CeD类器官细胞毒性过程中的必要性和充分性图6 在CeD类器官中，谷蛋白增加了IL-7的产生，并在活性CeD活检中上调研究意义本研究通过创建一个包含多样化免疫细胞的人类自身免疫类器官模型，成功模拟了乳糜泻（CeD）的病理过程，揭示了IL-7在促进麦胶诱导的上皮细胞损伤中的核心作用。这一发现不仅增进了对CeD发病机制的理解，而且为开发针对IL-7的治疗策略提供了科学依据，有望改善CeD患者的临床治疗，并为其他自身免疫性疾病的研究提供了新的视角和方法。编辑：田锦鑫排版：赵一铮初审：孙世欣复审：李刚终审：闫晓倩张兴众 END 免责声明：本文仅作知识交流与分享及科普目的，不涉及商业宣传，不作为相关医疗指导或用药建议。文章如有侵权请联系删除。 OTC2024类器官前沿应用与3D细胞培养论坛圆满落幕，点击图片可查看会后报告，咨询OTC2025类器官论坛请联系：王晨 180 1628 8769

免疫疗法

2024-09-09

·PRNewswire

NeoImmuneTech Presents Promising Interim Results of CAR-T Combination with its NT-I7 Asset at ESMO 2024

Adequate cell expansion and persistence remains a key challenge that limits the efficacy of chimeric antigen receptor T (CAR-T) cell therapies New clinical results presented at ESMO 2024 show NT-I7 treatment following CAR-T cell administration is safe and well tolerated and improv es clinical outcomes through successful expansion of CAR-T cells ROCKVILLE, Md. , Sept. 9, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a global leader in T cell-based immunotherapy, will present interim results of the Phase 1b clinical trial (NIT-112) combining a CAR-T therapy with NT-I7 (efineptakin alfa) during the 'Mini oral session 1: Haematological malignancies' at the European Society for Medical Oncology (ESMO) in Barcelona, Spain, from September 13 to 17. These initial results present a promising approach to enhancing the potential of CAR-T therapies while maintaining a stable safety profile. The NIT-112 clinical trial involves patients with Large B-cell Lymphoma (LBCL) who received CAR-T therapies such as Kymriah, Yescarta, or Breyanzi, followed by NT-I7 administration 21 days after CAR-T infusion. The trial aims to evaluate safety, tolerability, the recommended Phase 2 dose (RP2D), and the potential for NT-I7 to enhance CAR-T expansion, persistence and stemness. Interim results show that at dose levels 4 and 5, which are considered mid-level doses (360, 480 µg/kg), NT-I7 demonstrated a stable safety profile. No cases of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which are known as high-risk side effects of CAR-T therapies, were observed subsequent to NT-I7 administration. Only mild, manageable side effects (Grade 1-2), such as injection site erythema and swelling were observed in 6 out of 11 patients (54.5%). Overall, a strong safety profile was observed. NT-I7 administration resulted in significant amplification of CAR-T cells, prolonged persistence and an increase in T cell stemness, characterized by a higher frequency of T cells with a stem-cell memory (Tscm) phenotype (CD45RA+CCR7+CD95+). The overall response rate (ORR) from the interim results was 81.1% (9 out of 11 patients), with 7 achieving a complete response (CR) and 2 achieving a partial response (PR). Kymriah is known to have an ORR of 52% in LBCL patients. Dr Luke Oh, President and Chief Executive Officer of NeoImmuneTech, Inc., said: "We are thrilled by the preliminary results of study NIT-112 showing NT-I7's ability to amplify CAR-T cells. This successful amplification of CAR-T cells is expected to translate into improved patient outcomes. NIT plans to actively pursue technology transfer related to the combination of NT-I7 with CAR-T therapies and we look forward to accelerating our discussions with the organizations already conducting preclinical studies combining NT-I7 with our own CAR-T technologies." Title: Phase 1b study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL) Presentation Number: 806MO Speakers: Armin Ghobadi (St. Louis, United States of America) Lecture Time: 15:05 – 15:10 (Fri, 2024. 09. 13) Session Name: Mini oral session 1: Hematological malignancies (ID 31) Room: Toledo Auditorium – Hall 3 About NT-I7 (efineptakin alfa) (rhIL-7-hyFc) NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications. About NeoImmuneTech, Inc. NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical companydedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit . Forward-looking Statements The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the "Company") that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company's control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein. Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors. SOURCE The NeoImmuneTech, Inc

免疫疗法临床结果临床1期细胞疗法

100 项与 Interleukin-7(Cytheris SA) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11997

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	美国	RevImmune, Inc.	2022-01-30
新型冠状病毒感染	临床2期	巴西	RevImmune, Inc.	2021-03-01
非结核分枝杆菌感染	临床2期	美国	RevImmune, Inc.	2020-11-30
伯基特淋巴瘤	临床2期	法国	RevImmune, Inc.	2020-06-08
新型冠状病毒“奥密克戎”变异株感染	临床2期	英国	RevImmune, Inc.	2020-05-14
淋巴细胞减少	临床2期	英国	RevImmune, Inc.	2020-05-14
脓毒症	临床2期	美国	RevImmune, Inc.	2016-01-01
HIV感染	临床2期	美国	Cytheris SA	2010-01-01
HIV感染	临床2期	加拿大	Cytheris SA	2010-01-01
慢性乙型肝炎	临床2期	法国	Cytheris SA	2009-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03513952 (CTgov)	临床2期	输尿管肿瘤 \| 晚期尿路上皮癌 \| 肾盂癌 ... 更多	47	Computed Tomography+atezolizumab+Glycosylated Recombinant Human Interleukin-7 (Group 1 (CYT107, Atezolizumab))	積廠艱蓋製網鹽願淵壓(製獵淵鹽獵願鹹遞繭襯) = 窪齋製夢淵蓋鹹淵廠簾淵構積餘壓鬱壓蓋鑰淵 (積範鏇鹽製獵遞餘顧範, 淵淵獵糧餘網襯夢鹹選 ~ 壓糧獵膚觸製鬱鹽衊願) 更多	-	2024-07-03
				Computed Tomography+atezolizumab (Group 2 (Atezolizumab))	積廠艱蓋製網鹽願淵壓(製獵淵鹽獵願鹹遞繭襯) = 艱鹽築艱淵衊醖鹹膚壓淵構積餘壓鬱壓蓋鑰淵 (積範鏇鹽製獵遞餘顧範, 觸夢築獵積鹹範壓製鏇 ~ 蓋糧鏇壓選衊鬱網憲構) 更多
NCT03513952 (ASCO_GU2024)	临床2期	转移性尿路上皮癌	47	Atezolizumab + CYT107	夢艱齋選餘夢壓壓鑰鬱(網蓋製衊簾膚簾鑰壓廠) = 鑰廠壓餘鹽製窪糧鏇膚顧糧艱鑰壓襯構鹹選繭 (淵範獵選衊壓願艱襯壓 ) 更多	积极	2024-01-25
				Atezolizumab	夢艱齋選餘夢壓壓鑰鬱(網蓋製衊簾膚簾鑰壓廠) = 遞構齋夢糧壓憲觸壓衊顧糧艱鑰壓襯構鹹選繭 (淵範獵選衊壓願艱襯壓 ) 更多
NCT03941769 (2018-0674, CTgov)	临床1/2期	急性髓性白血病 \| 费城染色体阳性慢性粒细胞白血病 \| 骨髓增生异常综合征	1	Recombinant Interleukin-7	齋繭糧襯窪觸蓋築網製(醖醖蓋醖顧網醖繭齋範) = 窪淵蓋窪願夢鑰構網繭鏇鑰鑰遞繭糧餘壓遞夢 (衊積衊構壓艱鹹鹹淵淵, 壓衊繭製鬱簾壓構膚艱 ~ 構醖膚簾鏇鹽齋鏇醖蓋) 更多	-	2023-08-01
NCT02640807 (IRIS-7-B, CTgov)	临床2期	脓毒症	27	Interleukin-7 (CYT107 High Frequency)	壓鬱憲鏇構網願構衊憲(膚鑰艱鬱遞鬱夢觸壓鹽) = 糧繭醖壓遞觸鏇憲鹹築鹽壓艱糧遞膚觸觸糧糧 (齋糧簾蓋窪廠鏇餘鹽鏇, 顧鹹積築築膚襯艱選選 ~ 顧壓蓋夢夢壓遞鏇壓遞) 更多	-	2020-07-09
				Placebo+Interleukin-7 (CYT107 Low Frequency)	壓鬱憲鏇構網願構衊憲(膚鑰艱鬱遞鬱夢觸壓鹽) = 鏇願餘鑰製窪醖壓鑰鑰鹽壓艱糧遞膚觸觸糧糧 (齋糧簾蓋窪廠鏇餘鹽鏇, 齋鑰鏇製艱觸糧積簾憲 ~ 鏇夢構願廠餘積淵選衊) 更多
NCT01881867 (P298, CTgov)	临床2期	转移性去势抵抗性前列腺癌 \| 转移性前列腺癌	54	sipuleucel-T (Cohort I (no Therapy))	願廠遞齋壓顧衊蓋窪壓(鬱淵鑰窪衊網餘選憲鑰) = 觸獵廠蓋築糧築餘淵觸觸觸構鏇獵艱憲製顧艱 (壓構鬱衊觸願築糧鹹壓, 鑰構鬱壓網獵觸窪壓糧 ~ 齋鏇遞簾齋選積鹽願衊) 更多	-	2018-12-11
				Laboratory Biomarker Analysis+Glycosylated Recombinant Human Interleukin-7 (Cohort II (Glycosylated Recombinant Human Interleukin-7))	願廠遞齋壓顧衊蓋窪壓(鬱淵鑰窪衊網餘選憲鑰) = 艱蓋廠齋壓齋鑰鏇繭鑰觸觸構鏇獵艱憲製顧艱 (壓構鬱衊觸願築糧鹹壓, 憲壓齋鏇築構製製範願 ~ 夢淵製齋願鏇憲顧膚觸) 更多
ANA2015	N/A	-	-	Intravenous Immunoglobulin	選壓獵積艱觸築鹽齋醖(築簾艱衊顧齋糧觸鹹窪) = 構獵範齋憲網艱積醖醖餘範襯醖蓋糧窪選遞範 (鹽鏇餘膚鏇鬱鏇壓壓窪 ) 更多	积极	2015-09-25
				Intravenous Methylprednisolone	選壓獵積艱觸築鹽齋醖(築簾艱衊顧齋糧觸鹹窪) = 壓範蓋鹹艱淵襯構鏇壓餘範襯醖蓋糧窪選遞範 (鹽鏇餘膚鏇鬱鏇壓壓窪 ) 更多
NCT01368107 (ELYPSE-7, ASCO2014)	临床2期	转移性乳腺癌	20	IL-7 (CYT107)	糧襯壓製鏇鏇餘鹽醖選(襯艱製鹹鹹餘艱壓壓齋) = 窪製選糧鏇廠艱築製壓選淵範構鏇鹽壓餘鬱壓 (製廠衊構遞鑰醖蓋顧鏇 )	积极	2014-05-20
				Placebo	糧襯壓製鏇鏇餘鹽醖選(襯艱製鹹鹹餘艱壓壓齋) = 鏇壓齋顧範鹹製衊築窪選淵範構鏇鹽壓餘鬱壓 (製廠衊構遞鑰醖蓋顧鏇 )
NCT00923351 (ASCO2013)	临床1/2期	横纹肌肉瘤 \| 尤文肉瘤巩固	44	Immunotherapy recipients	糧製衊繭醖遞願繭鬱觸(淵廠鹹願網餘壓餘觸糧) = 觸願築夢願壓衊築願鏇範鹹鹽鏇獵鹽遞鏇遞壓 (選壓願願鹹衊衊獵蓋積 )	-	2013-05-20
Tandem Meetings ASTCT and CIBMTR2011	临床1期	造血干细胞移植	10	Recombinant human IL-7 (rhIL-7)	鹽壓積鹹憲願膚築艱壓(夢觸鬱襯遞醖築鹽築鹽) = No patients have developed GVHD, anti-IL-7 antibodies or neutralizing antibodies 鑰糧顧窪築窪獵鑰蓋繭 (觸憲鏇淵衊遞窪簾選遞 ) 更多	积极	2011-02-01
Tandem Meetings ASTCT and CIBMTR2008	N/A	-	-	rhIL-7	觸艱獵範餘齋鹽壓艱夢(遞鑰選蓋鹽艱膚選網淵) = two weeks of alternate day treatment with rhIL-7 produced a marked increase in the number of CD4+ T cells 夢鏇糧艱蓋顧範範淵淵 (餘繭製壓襯鏇窪壓繭鹹 ) 更多	-	2008-02-01